The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ARS PHARMACEUTICALS INC | COM | 82835W108 | 12,797,194 | 1,910,029 | SH | SOLE | 1,910,029 | 0 | 0 | |||
ARVINAS INC | COM | 04335A105 | 7,129,570 | 287,251 | SH | SOLE | 287,251 | 0 | 0 | |||
C4 THERAPEUTICS INC | COM STK | 12529R107 | 1,033,607 | 375,857 | SH | SOLE | 375,857 | 0 | 0 | |||
CULLINAN ONCOLOGY INC | COM | 230031106 | 13,139,520 | 1,221,145 | SH | SOLE | 1,221,145 | 0 | 0 | |||
EQRX INC | COM | 26886C107 | 24,374,229 | 13,104,424 | SH | SOLE | 13,104,424 | 0 | 0 | |||
KINNATE BIOPHARMA INC | COM | 49705R105 | 7,058,324 | 2,329,480 | SH | SOLE | 2,329,480 | 0 | 0 | |||
KRONOS BIO INC | COM | 50107A104 | 2,496,644 | 1,451,537 | SH | SOLE | 1,451,537 | 0 | 0 | |||
PMV PHARMACEUTICALS INC | COM | 69353Y103 | 2,950,238 | 471,284 | SH | SOLE | 471,284 | 0 | 0 | |||
ORIC PHARMACEUTICALS INC | COM | 68622P109 | 33,257,141 | 4,285,714 | SH | SOLE | 4,285,714 | 0 | 0 | |||
RELAY THERAPEUTICS INC | COM | 75943R102 | 11,915,157 | 948,659 | SH | SOLE | 948,659 | 0 | 0 | |||
REVOLUTION MEDICINES INC | COM | 76155X100 | 129,457,401 | 4,839,529 | SH | SOLE | 4,839,529 | 0 | 0 | |||
THESEUS PHARMACEUTICALS INC | COM | 88369M101 | 5,703,522 | 611,310 | SH | SOLE | 611,310 | 0 | 0 | |||
TYRA BIOSCIENCES INC | COM | 90240B106 | 42,891,451 | 2,518,582 | SH | SOLE | 2,518,582 | 0 | 0 |